Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

Keith W. Pratz, MD, Ivana Gojo, MD, Judith E. Karp, MD, Leo Luznik, MD, B. Douglas Smith, MD, Richard J Jones, MD, Jackie Greer, RN, Christopher Gocke, MD, Maria R. Baer, MD, Vu H. Duong, MD, John J Wright, MD PhD, Michelle A. Rudek, PharmD, PhD, Ashkan Emadi, MD, PhD, Mark J. Levis, MD PhD

Blood (2015) 126 (23): 3164.

https://doi.org/10.1182/blood.V126.23.3164.3164

Published: 2015

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD, John M. Pagel, MD, PhD, B. Douglas Smith, MD, Jacqueline M Greer, RN, D. Michelle Drye, RN, Kelly M. Smith, MD, Kathleen Dorcy, RN, John J Wright, MD, PhD, L. Austin Doyle, MD, PhD, Elizabeth Garrett-Mayer, PhD, Elihu H. Estey, MD

Blood (2010) 116 (21): 186.

https://doi.org/10.1182/blood.V116.21.186.186

Published: 2010

Journal Articles

Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.

Sowjanya Reganti, MD, Edith Kabba, PhD, Wendy Stock, MD, John J. Wright, MD, PhD, John E. Godwin, MD, MS, Ameet R. Kini, MD, PhD

Blood (2007) 110 (11): 4726.

https://doi.org/10.1182/blood.V110.11.4726.4726

Published: 2007

Journal Articles

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Rebecca M. Ricklis, MS, Judith E. Karp, MD, Eric J. Feldman, MD, Suzanne Galkin, BA, Jacqueline M. Greer, RN, Valerie Ironside, CRNP, Kim Mirjafary, Timothy D. Talbot, BA, Lawrence E. Morris, MD, John J. Wright, MD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2007) 110 (11): 914.

https://doi.org/10.1182/blood.V110.11.914.914

Published: 2007

Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD

Blood (2006) 108 (11): 426.

https://doi.org/10.1182/blood.V108.11.426.426

Published: 2006

Journal Articles

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Judith E. Karp, MD, Ivana Gojo, MD, Jacqueline Greer, R.N., B. Douglas Smith, MD, Maureen Klein, R.N., Jeffery E. Lancet, MD, Steven D. Gore, MD, Lawrence Morris, MD, Alain Thibault, MD, Mary Ellen Rybak, MD, John J. Wright, MD, PhD

Blood (2005) 106 (11): 2783.

https://doi.org/10.1182/blood.V106.11.2783.2783

Published: 2005

Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD

Blood (2004) 104 (11): 874.

https://doi.org/10.1182/blood.V104.11.874.874

Published: 2004

NARROW

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only